By Benjamin Chiou
Date: Tuesday 14 Apr 2026
(Sharecast News) - Pharmaceutical and medical tech group Johnson & Johnson raised its 2026 outlook on Tuesday after first-quarter results marginally beat Wall Street estimates on the back of strong growth from its oncology drug portfolio.
| Johnson & Johnson agrees to pay £13bn for Switze... | 28-Apr-2011 | The Independent |
| S&N DRIFTS AS BID HOPES SLIP | 19-Apr-2011 | Express & Star |
| J&J asks judge to dismiss kickback case | 08-Oct-2010 | Wall Street Journal |
| Genzyme Again Rejects Sanofi’s Bid | 08-Oct-2010 | New York Times |
| Johnson & Johnson buying vaccine maker Crucell | 07-Oct-2010 | USA Today |
| Currency | US Dollars |
| Share Price | $ 228.39 |
| Change Today | $ -5.81 |
| % Change | -2.48 % |
| 52 Week High | $248.56 |
| 52 Week Low | $149.79 |
| Volume | 18,989,761 |
| Shares Issued | 2,407.94m |
| Market Cap | $549,949m |
| RiskGrade | 87 |
| Strong Buy | 6 |
| Buy | 8 |
| Neutral | 12 |
| Sell | 0 |
| Strong Sell | 0 |
| Total | 26 |

| Time | Volume / Share Price |
| 16:00 | 7,251,027 @ $228.39 |
| 16:00 | 4,896 @ $228.39 |
| 16:00 | 2,000 @ $228.39 |
| 16:00 | 160 @ $228.38 |
| 15:59 | 400 @ $228.40 |
You are here: research